Chimigen Biomedical is a clinical-stage immunotherapy company developing a new class of Engineered Fc-Targeted Immune-Priming Therapeutics (IPTs) platform-powered by our SynNeogen® technology that address a fundamental limitation of today's immuno-oncology and antiviral modalities—the inability to effectively initiate de novo T-cell immunity in immune-cold tumors and chronic viral infections.
ChimiVac Inc is a wholly-owned subsidiary of Chimigen Bio, located in NewYork City, USA.
In January, the company was honored on Deloitte China's "Rising Star" list.
In April, the company was awarded the Third Prize at the 2025 "Rong Piao Cup" Innovation Competition.
In May, SN2001 received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA).
In May, the company was selected as one of the first batch of enterprises on the "Golden Panda Future Star" list in Chengdu High-Tech Zone.
In July, the company was recognized as a Specialized, Sophisticated, Distinctive, and Innovative Small and Medium-sized Enterprise in Sichuan Province and won the Excellence Award at the 9th "Maker China" Pharmaceutical and Health Small and Medium-sized Enterprises Innovation and Entrepreneurship Competition.
In September, the Guangzhou subsidiary was established and moved into the BeiGene Innovation Center (BIC).
In July, Launched ChimiVac (u.s.Subsidiary) in NewYork.
In June, ChimigenBio was founded in the Tianfu International Bio-Town.
In November, the company completed an angel round of financing exceeding 100 million yuan.
2025
2024
2023
2022
Chimigen Biomedical (Chengdu) Co., Ltd.
1601, Tower F2, Chengdu Tianfu International Bio-Town, Chengdu, Sichuan
Tel：028-60610771
E-mail：contact@chimigen.com
Copyright© 2025 Chimigen Biomedical (Chengdu) Co., Ltd.
